OM:XBRANE

Stock Analysis Report

Executive Summary

Xbrane Biopharma AB (publ), a biopharmaceutical company, develops and manufactures biosimilars and generic long acting injectables.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.

Risks

  • Xbrane Biopharma has significant price volatility in the past 3 months.
  • Xbrane Biopharma is covered by less than 3 analysts.

Share Price & News

How has Xbrane Biopharma's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-9.0%

OM:XBRANE

-3.0%

SE Biotechs

-1.2%

SE Market


1 Year Return

-56.5%

OM:XBRANE

-19.7%

SE Biotechs

-2.6%

SE Market

XBRANE underperformed the Biotechs industry which returned -19.7% over the past year.

XBRANE underperformed the Market in Sweden which returned -2.6% over the past year.


Share holder returns

XBRANEIndustryMarket
7 Day-9.0%-3.0%-1.2%
30 Day-12.2%-10.3%-3.6%
90 Day-27.0%-3.5%-2.8%
1 Year-54.1%-56.5%-19.4%-19.7%1.4%-2.6%
3 Year-29.6%-33.3%41.8%30.9%25.3%6.6%
5 Yearn/a52.2%50.9%44.9%14.3%

Price Volatility Vs. Market

How volatile is Xbrane Biopharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Xbrane Biopharma undervalued based on future cash flows and its price relative to the stock market?

1.71x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Xbrane Biopharma to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Xbrane Biopharma to establish if it is available at substantial discount.


Price Based on Earnings

Xbrane Biopharma is loss making, we can't compare its value to the SE Biotechs industry average.

Xbrane Biopharma is loss making, we can't compare the value of its earnings to the Sweden market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Xbrane Biopharma, we can't assess if its growth is good value.


Price Based on Value of Assets

Xbrane Biopharma is good value based on assets compared to the SE Biotechs industry average.


Next Steps

Future Growth

How is Xbrane Biopharma expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

-22.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Xbrane Biopharma's revenue is expected to grow significantly at over 20% yearly.

Xbrane Biopharma is not considered high growth as it is expected to be loss making for the next 1-3 years.

Xbrane Biopharma's revenue growth is expected to exceed the Sweden market average.

Unable to compare Xbrane Biopharma's earnings growth to the Sweden market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Xbrane Biopharma's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Xbrane Biopharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Xbrane Biopharma performed over the past 5 years?

-27.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Xbrane Biopharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Xbrane Biopharma's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Xbrane Biopharma's 1-year growth to the SE Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Xbrane Biopharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Xbrane Biopharma has efficiently used its assets last year compared to the SE Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Xbrane Biopharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

  • Explore strong past performing companies in the Pharmaceuticals & Biotech industry.

Financial Health

How is Xbrane Biopharma's financial position?


Financial Position Analysis

Xbrane Biopharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Xbrane Biopharma's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Xbrane Biopharma's level of debt (44.6%) compared to net worth is high (greater than 40%).

Unable to establish if Xbrane Biopharma's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 4.4x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Whilst loss making Xbrane Biopharma has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.

Whilst loss making Xbrane Biopharma has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -45.7% per year.


Next Steps

Dividend

What is Xbrane Biopharma's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Xbrane Biopharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Xbrane Biopharma's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Xbrane Biopharma has not reported any payouts.

Unable to verify if Xbrane Biopharma's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Xbrane Biopharma has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Xbrane Biopharma's salary, the management and board of directors tenure and is there insider trading?

4.6yrs

Average management tenure


CEO

Martin Åmark (39yo)

4.6yrs

Tenure

kr1,402,000

Compensation

Mr. Martin Åmark serves as the Head of Investor Relation since February 14, 2019 and also serves as Chief Executive Officer of Xbrane Biopharma AB (publ). Mr. Åmark has 8 years of experience from Bain & Co ...


CEO Compensation Analysis

Martin's remuneration is about average for companies of similar size in Sweden.

Martin's compensation has increased whilst company is loss making.


Management Age and Tenure

4.6yrs

Average Tenure

38yo

Average Age

The tenure for the Xbrane Biopharma management team is about average.


Board Age and Tenure

4.6yrs

Average Tenure

62.5yo

Average Age

The tenure for the Xbrane Biopharma board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

Buykr21,22204 Apr 19
Peter Edman
EntityIndividual
Role
Member of the Board of Directors
Director
Shares540
Max Pricekr39.30
Buykr94,80001 Apr 19
David Vikström
EntityIndividual
Role
Chief Technology Officer
Chief Technology Officer
Shares3,160
Max Pricekr30.00
Sellkr14320 Mar 19
Siavash Bashiri
EntityIndividual
Role
Chief Operating Officer
COO, Head of Biosimilars & Deputy CEO
Shares3
Max Pricekr47.50
Sellkr4804 Feb 19
Siavash Bashiri
EntityIndividual
Role
Chief Operating Officer
COO, Head of Biosimilars & Deputy CEO
Shares1
Max Pricekr47.50
Buykr23,50616 Jan 19
Susanna Helgesen
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares500
Max Pricekr47.02
Buykr81,28516 Jan 19
David Vikström
EntityIndividual
Role
Chief Technology Officer
Chief Technology Officer
Shares1,735
Max Pricekr46.85
Buykr102,25615 Jan 19
Siavash Bashiri
EntityIndividual
Role
Chief Operating Officer
COO, Head of Biosimilars & Deputy CEO
Shares2,200
Max Pricekr46.48

Ownership Breakdown


Management Team

  • Susanna Helgesen (34yo)

    Chief Financial Officer

    • Tenure: 2.3yrs
  • Samuel Wagner

    Co-Founder & Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Paolo Sarmientos (62yo)

    Head of long-acting Injectables

    • Tenure: 0.0yrs
  • Martin Åmark (39yo)

    CEO & Head of Investor Relation

    • Tenure: 4.6yrs
    • Compensation: kr1.40m
  • Siavash Bashiri (36yo)

    COO, Head of Biosimilars & Deputy CEO

    • Tenure: 4.6yrs
    • Compensation: kr1.33m
  • David Vikström (42yo)

    Chief Technology Officer

    • Tenure: 5.6yrs
  • Dina Jurman (37yo)

    Head of Clinical Affairs

    • Tenure: 1.9yrs

Board Members

  • Björn Nilsson (63yo)

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Maris Hartmanis (66yo)

    Director

    • Tenure: 4.6yrs
    • Compensation: kr137.00k
  • Peter Edman (65yo)

    Director

    • Tenure: 4.6yrs
    • Compensation: kr137.00k
  • Giorgio Chirivi (58yo)

    Director

    • Tenure: 3.2yrs
    • Compensation: kr137.00k
  • Gunnar Von Heijne

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Joen Luirink

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Samuel Wagner

    Co-Founder & Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • David Drew

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Karin Wingstrand (62yo)

    Director

    • Tenure: 4.6yrs
    • Compensation: kr137.00k
  • Anders Tullgren (58yo)

    Chairman of the Board

    • Tenure: 1.3yrs
    • Compensation: kr175.00k

Company Information

Xbrane Biopharma AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Xbrane Biopharma AB (publ)
  • Ticker: XBRANE
  • Exchange: OM
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr420.835m
  • Shares outstanding: 15.42m
  • Website: https://www.xbrane.com

Number of Employees


Location

  • Xbrane Biopharma AB (publ)
  • Banvaktsvägen 22
  • Solna
  • Stockholm County
  • 171 48
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XBRANEOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKFeb 2016

Biography

Xbrane Biopharma AB (publ), a biopharmaceutical company, develops and manufactures biosimilars and generic long acting injectables. The company is developing Xlucane, a ranibizumab biosimilar that is in Ph ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/18 21:53
End of Day Share Price2019/08/16 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.